Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
A Stable and Specific way to Target Cells in the Nervous System

A Stable and Specific way to Target Cells in the Nervous System

An interview with Eugenia Kuteeva conducted at SfN 2018, by Alina Shrourou, BSc.

How can Neuroscience markers be used to advance our understanding of the brain?

Neuroscience markers are monoclonal antibodies, developed for identification of the main anatomical and histochemical cell types in the central nervous system. They can therefore be used as markers of the structural and chemical neuroanatomy. These antibodies can also be employed in multiplexing studies, to look, for example, at the expression of your protein of interest in a particular cell type in the nervous system.

Please outline the Neuroscience Marker Panel provided by Atlas Antibodies and which neural lineage and signalling markers they can target.

Our Neuroscience marker panel antibodies are a part of our catalogue of monoclonal antibodies. They target the main cell types in the nervous system, including neurons, astrocytes and oligodendrocytes. We will soon be adding also some microglial markers, which are currently under development. And already now we provide markers for the main neurotransmitter systems, including GABA, glutamate, acetylcholine, dopamine and serotonin systems.

How do Atlas Antibodies develop and validate these markers?

It is important to mention that we have chosen the targets for development of the Neuroscience markers antibodies, based on scientific knowledge on most relevant proteins for identification of different cell types in the brain.

We have an established protocol for development of our monoclonal antibodies, which starts with a careful selection of the most appropriate antigen for immunization. Following immunization, a number of ELISA positive clones are tested in functional applications in order to select the optimal ones for establishing the hybridomas, from which the purified monoclonal antibodies are finally produced. We test the purified monoclonal antibodies thoroughly in all relevant applications before approving and releasing them as products. In addition, all PrecisA Monoclonals are supported with isotype and, when relevant, epitope data.

We put a great effort into the proper validation of our antibodies by following the directions of the International Working Group for Antibody Validation (IWGAV), which recommends the five pillars of validation – genetic, orthogonal, independent antibody, expression of tagged proteins and immunocapture mass spectrometry. We apply these guidelines when validating our antibodies, which we do in the application specific manner.

Furthermore, the majority of PrecisA Monoclonals within the Neuroscience marker panel are tested and approved for use in both human, mouse and rat tissues, which can be beneficial for e.g. translational studies.

What are the other areas of research you provide the antibodies for?

Alongside our Neuroscience marker panel monoclonals, we also have monoclonal antibodies targeting early development of the nervous system, cortical layers markers, as well as organelle, SOX proteins, stem cells and EMT markers to name a few.

On our website, we provide information about the applications and species, which antibodies have been approved for. For the neuroscience marker panel in particular, we have tested and approved them for immunohistochemistry use in human, mouse, and rat tissues.

What can Atlas Antibodies provide to the neuroscience research community by being at Neuroscience 2018?

We put a great effort into developing the most specific and selective antibodies that meet the researchers needs. We take a great care in ensuring that the antibodies are functioning properly for our customers in all recommended applications.

We are here to meet with and talk to scientists in the neuroscience community. We always look forward to events like SfN to be able to discuss our products with our customers in person and to help them to meet their research challenges by providing technical and scientific advice.


Researchers often come to us to discuss which antibodies can be useful for their studies. For example, whether we have antibodies against their specific targets of interest, or which antibodies can be used for identifying specific cell types, groups of cells or particular structures in the nervous system. They may also have questions on experimental protocols. We are present here with our many years of neuroscience expertise to try to meet up and help scientist with their questions.

About Eugenia Kuteeva

Eugenia Kuteeva is a Principle Scientist working with development and validation of novel monoclonal antibodies (PrecisA Monoclonals) at Atlas Antibodies since 2012. Dr. Kuteeva holds a PhD degree in Neuroscience from the Department of Neuroscience at Karolinska Institute. She has a broad experience in life sciences from both academia and industry. Dr. Kuteeva has received several prestigious grants and has published more than 20 peer reviewed scientific papers, reviews and book chapters.

About author

Related Articles